Callie J. Donahue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Callie J. Donahue has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Robert A. Davey
Boston University
2 shared publications - Albert-László Barabási
Network Science Institute, Northeastern University, Boston, MA, USA.
1 shared publication Ashley A. Adair
Rochester Institute of Technology
1 shared publicationAvantika Dhabaria
Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016
1 shared publication- Bearach Miwatani-Minter
Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, USA
1 shared publication Beatrix Ueberheide
Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016
1 shared publication
Latest Publications
- Open Access
Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo
The SARS-CoV-2 pandemic has caused widespread illness, loss of life, and socioeconomic disruption that is unlikely to resolve until vaccines are widely adopted, and effective therapeutic treatments become established. Here, a well curated and annotated library of 6710 clinical and preclinical molecules, covering diverse chemical scaffolds and known host targets was evaluated for inhibition of SARS-CoV-2 infection in multiple infection models. Multi-concentration, high-content immunocytofluorescence-based screening identified 172 strongly active small molecules, including 52 with submicromolar potencies. The active molecules were extensively triaged by in vitro mechanistic assays, including human primary cell models of infection and the most promising, obatoclax, was tested for in vivo efficacy. Structural and mechanistic classification of compounds revealed known and novel chemotypes and potential host targets involved in each step of the virus replication cycle including BET proteins, microtubule function, mTOR, ER kinases, protein synthesis and ion channel function. In the mouse disease model obatoclax effectively reduced lung virus load by 10-fold. Overall, this work provides an important, publicly accessible, foundation for development of novel treatments for COVID-19, establishes human primary cell-based pharmacological models for evaluation of therapeutics and identifies new insights into SARS-CoV-2 infection mechanisms. Significance A bioinformatically rich library of pharmacologically active small molecules with diverse chemical scaffolds and including known host targets were used to identify hundreds of SARS-CoV-2 replication inhibitors using in vitro, ex vivo, and in vivo models. Extending our previous work, unbiased screening demonstrated a propensity for compounds targeting host proteins that interact with virus proteins. Representatives from multiple chemical classes revealed differences in cell susceptibility, suggesting distinct dependencies on host factors and one, Obatoclax, showed 90% reduction of lung virus loads in the mouse disease model. Our findings and integrated analytical approaches will have important implications for future drug screening and how therapies are developed against SARS-CoV-2 and other viruses.
Open AccessIdentification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo
The SARS-CoV-2 pandemic has caused widespread illness, loss of life, and socioeconomic disruption that is unlikely to resolve until vaccines are widely adopted, and effective therapeutic treatments become established. Here, a well curated and annotated library of 6710 clinical and preclinical molecules, covering diverse chemical scaffolds and known host targets was evaluated for inhibition of SARS-CoV-2 infection in multiple infection models. Multi-concentration, high-content immunocytofluorescence-based screening identified 172 strongly active small molecules, including 52 with submicromolar potencies. The active molecules were extensively triaged by in vitro mechanistic assays, including human primary cell models of infection and the most promising, obatoclax, was tested for in vivo efficacy. Structural and mechanistic classification of compounds revealed known and novel chemotypes and potential host targets involved in each step of the virus replication cycle including BET proteins, microtubule function, mTOR, ER kinases, protein synthesis and ion channel function. In the mouse disease model obatoclax effectively reduced lung virus load by 10-fold. Overall, this work provides an important, publicly accessible, foundation for development of novel treatments for COVID-19, establishes human primary cell-based pharmacological models for evaluation of therapeutics and identifies new insights into SARS-CoV-2 infection mechanisms. Significance A bioinformatically rich library of pharmacologically active small molecules with diverse chemical scaffolds and including known host targets were used to identify hundreds of SARS-CoV-2 replication inhibitors using in vitro, ex vivo, and in vivo models. Extending our previous work, unbiased screening demonstrated a propensity for compounds targeting host proteins that interact with virus proteins. Representatives from multiple chemical classes revealed differences in cell susceptibility, suggesting distinct dependencies on host factors and one, Obatoclax, showed 90% reduction of lung virus loads in the mouse disease model. Our findings and integrated analytical approaches will have important implications for future drug screening and how therapies are developed against SARS-CoV-2 and other viruses.
- Open Access
- 7 April 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (17)
ORF10–Cullin-2–ZYG11B complex is not required for SARS-CoV-2 infection
Significance: Understanding the functions of the genes encoded in the SARS-CoV-2 genome is imperative to understanding its pathogenesis. One unique feature of the SARS-CoV-2 genome is ORF10, a small putative protein that was hypothesized to promote infection by hijacking a cellular E3 ubiquitin ligase, CRL2 ZYG11B . Here, we investigate whether ORF10 hijacks CRL2 ZYG11B or functions in other ways, such as to inhibit CRL2 ZYG11B or be degraded by it. We do not find evidence that ORF10 regulates or is regulated by CRL2 ZYG11B , and, furthermore, we find that ZYG11B and its paralog are dispensable for SARS-CoV-2 infection in cultured cells.
- 7 April 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (17)
Open AccessORF10–Cullin-2–ZYG11B complex is not required for SARS-CoV-2 infection
Significance: Understanding the functions of the genes encoded in the SARS-CoV-2 genome is imperative to understanding its pathogenesis. One unique feature of the SARS-CoV-2 genome is ORF10, a small putative protein that was hypothesized to promote infection by hijacking a cellular E3 ubiquitin ligase, CRL2 ZYG11B . Here, we investigate whether ORF10 hijacks CRL2 ZYG11B or functions in other ways, such as to inhibit CRL2 ZYG11B or be degraded by it. We do not find evidence that ORF10 regulates or is regulated by CRL2 ZYG11B , and, furthermore, we find that ZYG11B and its paralog are dispensable for SARS-CoV-2 infection in cultured cells.
- Open Access
- 1 January 2019
- Published by CourseSource in CourseSource
- Vol. 6
A Close-Up Look at PCR
CourseSource is an open-access journal of peer-reviewed teaching resources for undergraduate biological sciences. We publish articles that are organized around courses in biological disciplines and aligned with learning goals established by professional societies representing those disciplines.
- 1 January 2019
- Published by CourseSource in CourseSource
- Vol. 6
Open AccessA Close-Up Look at PCR
CourseSource is an open-access journal of peer-reviewed teaching resources for undergraduate biological sciences. We publish articles that are organized around courses in biological disciplines and aligned with learning goals established by professional societies representing those disciplines.